TLDR Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.
The document discusses the repurposing of H1-receptor antagonists, specifically cetirizine, loratadine, and fexofenadine, using custom-coded software to analyze data from clinicaltrials.gov. The software analyzed metadata from 70 to 104 studies per drug, identifying potential new uses for these drugs in conditions such as asthma, infusion-associated reactions, G-CSF-associated bone pain, alopecia, and COVID-19. For alopecia, topical cetirizine was found to be less effective than minoxidil in improving hair density, but it might have a longer-lasting effect. The document also mentions a study involving 61,627 women that found loratadine and desloratadine improved survival rates in breast cancer and melanoma patients. However, the authors highlight limitations, including reliance on information provided by study authors on clinicaltrials.gov and the challenge of trials not having published results.
1 citations,
July 2023 in “Cureus” Some treatments for hereditary hair loss are effective but vary in results and side effects; new therapies show promise but need more research.
December 2022 in “Archives of Dermatological Research” Adding cetirizine to minoxidil improves hair growth and thickness in women with androgenetic alopecia.
August 2022 in “Journal of Cosmetic Dermatology” 1% topical cetirizine may help treat hair loss but is less effective than minoxidil.
7 citations,
April 2021 in “Journal of Pharmacy and Pharmaceutical Sciences” Cetirizine 1% helps hair growth in men with no major side effects, but minoxidil 5% works better.
5 citations,
January 2021 in “Journal of Cosmetic Dermatology” Topical cetirizine 1% promotes hair growth in male androgenetic alopecia patients.
Use the least toxic, most specific treatments for skin diseases, considering side effects and individual patient needs.
5 citations,
December 2022 in “Annals Academy of Medicine Singapore” Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.
January 2016 in “Springer eBooks” Understanding drug interactions, side effects, and patient-specific factors is crucial for effective dermatological care.
159 citations,
March 2014 in “Journal of The American Academy of Dermatology” Some skin medications are safe during pregnancy and breastfeeding, but others can harm the baby and should be avoided.
73 citations,
March 2014 in “Journal of The American Academy of Dermatology” Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.
